Updated:
Inmune Bio
Inmune Bio is a clinical-stage biotech led by RJ Tesi, developing a selective TNF inhibitor for neuroinflammation in Alzheimer's disease.
Inmune Bio
Inmune Bio was founded in 2015 and structured as a clinical-stage immunology company, with RJ Tesi serving as CEO since its early days. The company focuses on harnessing the innate immune system to combat disease, developing therapies that target neuroinflammation — a root cause believed to drive conditions such as Alzheimer's disease and treatment-resistant depression. The pipeline is anchored by XPro1595, a selective, dominant-negative tumor necrosis factor (TNF) inhibitor that spares the beneficial transmembrane TNF while neutralizing the inflammatory soluble TNF. This strategy underpins Phase 2 trials for Alzheimer's disease and treatment-resistant depression, positioning the firm in a niche away from conventional monoclonal antibody approaches. A second program, INKmune, is a biologic natural killer cell therapy aimed at liquid and solid tumors, broadening the firm's therapeutic scope into oncology. The company's development programs are conducted in clinical sites across the United States and Australia. Inmune Bio operates from its headquarters in Boca Raton, Florida, with a small executive team directing the clinical progress. The company does not disclose a deployment or AUM figure, as it functions as a drug developer rather than an allocator of external capital, funding its operations through equity raises and partnership structures common to biotech firms. In January 2024, the company reported that the independent Data Safety Monitoring Board recommended the continuation of its Phase 2 Alzheimer's trial without modification following a pre-planned safety review. Structurally, Inmune Bio differentiates itself through its mechanism-specific targeting of neuroinflammation, a pathway that treats immune dysfunction as the primary driver of neurodegeneration rather than a secondary symptom. This contrasts with the market's heavy focus on beta-amyloid clearance, giving the firm a defined, high-risk scientific thesis for a disease where monotherapeutic failures dominate the historical record.
General information
Firm type
Asset Manager
Year founded
2015
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boca Raton
Corporate office
Boca Raton, FL, United States
Principals
RJ Tesi
Chief Executive Officer
David Moss
Chief Financial Officer
Sector focus
Frequently asked questions
What is Inmune Bio's lead drug candidate?
XPro1595 is a next-generation, selective tumor necrosis factor (TNF) inhibitor that targets soluble TNF while sparing transmembrane TNF. The company is evaluating it in Phase 2 trials for Alzheimer's disease and treatment-resistant depression, aiming to reduce neuroinflammation, a core driver of these conditions.
How does Inmune Bio's approach to Alzheimer's differ from approved therapies?
Unlike anti-amyloid antibodies that clear plaque build-up, Inmune Bio targets neuroinflammation via soluble TNF neutralization. The scientific premise posits that chronic immune dysfunction within the brain contributes directly to the synaptic loss and cognitive decline seen in Alzheimer's, a hypothesis not addressed by current FDA-approved monoclonal antibodies.
Does Inmune Bio have programs beyond Alzheimer's disease?
Yes. The XPro1595 platform is also being studied in treatment-resistant depression. Additionally, the company is developing INKmune, a biologic natural killer cell therapy designed to target both hematologic malignancies and solid tumors, providing a separate immuno-oncology pipeline.
What is the mechanism of action for XPro1595?
XPro1595 is a dominant-negative TNF biologic — it works by selectively neutralizing soluble TNF, the form that drives chronic inflammation, without affecting transmembrane TNF, which is essential for immune surveillance and neuronal function. This selectivity is designed to maximize anti-inflammatory benefit while limiting immunosuppressive side effects common with broader TNF blockers.
Is Inmune Bio a family office or an investment vehicle?
No. Despite being categorized variably in external databases, Inmune Bio is a publicly traded biotechnology company. It does not manage a portfolio of external investments or function as a wealth-preservation structure; it is a drug development firm funded through equity financing to advance its clinical programs.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: